

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Underwood, TJ;Hayden, AL;Derouet, M;Garcia, E;Noble, F;White, MJ;Thirdborough, S;Mead, A;Clemons, N;Mellone, M;Uzoho, C;Primrose, JN;Blaydes, JP;Thomas, GJ

Title:

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma

Date:

2015-02-01

Citation:

Underwood, T. J., Hayden, A. L., Derouet, M., Garcia, E., Noble, F., White, M. J., Thirdborough, S., Mead, A., Clemons, N., Mellone, M., Uzoho, C., Primrose, J. N., Blaydes, J. P. & Thomas, G. J. (2015). Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. *Journal of Pathology*, 235 (3), pp.466-477. <https://doi.org/10.1002/path.4467>.

Persistent Link:

<https://hdl.handle.net/11343/263367>

License:

CC BY

Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma

Timothy J Underwood,^{1,*} Annette L Hayden,^{1,#} Mathieu Derouet,² Edwin Garcia,¹ Fergus Noble,¹ Michael J White,¹ Steve Thirdborough,¹ Abbie Mead,¹ Nicholas Clemons,^{3,4,5} Massimiliano Mellone,¹ Chudy Uzoho,¹ John N Primrose,¹ Jeremy P Blaydes¹ and Gareth J Thomas¹

¹ Cancer Sciences Unit, Somers Cancer Research Building, University of Southampton, UK

² University Health Network, Thoracic Surgery Clinic, University of Toronto, Canada

³ Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

⁴ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia

⁵ Department of Surgery (St. Vincent's Hospital), University of Melbourne, Parkville, Victoria, Australia

*Correspondence to: TJ Underwood, Cancer Sciences Division, University of Southampton, Somers Cancer Research Building, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK. E-mail: tju@soton.ac.uk

#These authors share co-first authorship.

Abstract

Interactions between cancer cells and cancer-associated fibroblasts (CAFs) play an important role in tumour development and progression. In this study we investigated the functional role of CAFs in oesophageal adenocarcinoma (EAC). We used immunohistochemistry to analyse a cohort of 183 EAC patients for CAF markers related to disease mortality. We characterized CAFs and normal oesophageal fibroblasts (NOFs) using western blotting, immunofluorescence and gel contraction. Transwell assays, 3D organotypic culture and xenograft models were used to examine the effects on EAC cell function and to dissect molecular mechanisms regulating invasion. Most EACs (93%) contained CAFs with a myofibroblastic (α -SMA-positive) phenotype, which correlated significantly with poor survival [$p = 0.016$; HR 7.1 (1.7–29.4)]. Primary CAFs isolated from EACs have a contractile, myofibroblastic phenotype and promote EAC cell invasion *in vitro* (Transwell assays, $p \leq 0.05$; organotypic culture, $p < 0.001$) and *in vivo* ($p \leq 0.05$). *In vitro*, this pro-invasive effect is modulated through the extracellular matrix protein periostin. Periostin is secreted by CAFs and acts as a ligand for EAC cell integrins $\alpha v \beta 3$ and $\alpha v \beta 5$, promoting activation of the PI3kinase–Akt pathway. In patient samples, periostin expression at the tumour cell–stromal interface correlates with poor overall and disease-free survival. Our study highlights the importance of the tumour stroma in EAC progression. Paracrine interaction between CAF-secreted periostin and EAC-expressed integrins results in PI3 kinase–Akt activation and increased tumour cell invasion. Most EACs contain a myofibroblastic CAF-rich stroma; this may explain the aggressive, highly infiltrative nature of the disease, and suggests that stromal targeting may produce therapeutic benefit in EAC patients.

© 2014 The Authors. *The Journal of Pathology* published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Keywords: CAFs; tumour microenvironment; oesophageal cancer; periostin

Received 31 July 2014; Revised 6 October 2014; Accepted 16 October 2014

No conflicts of interest were declared.

Introduction

Oesophageal cancer is associated with extremely poor overall survival; 60–70% of patients present with late-stage disease, too advanced for treatment with curative intent, and in those patients who are suitable for multimodal therapy, 5 year survival is only 35% [1]. This is partly due to the mechanically compliant oesophageal anatomy, which allows symptomless tumour expansion [2]. Additionally, tumour invasion and metastasis are facilitated by the absence of an outer serosal layer and the presence of a rich lymphatic plexus. Depth of invasion and nodal metastasis are both

prognostic, and improving survival rates will require an increased understanding of the molecular mechanisms regulating local and regional tumour spread.

Although most cancer-related research has focused on tumour cells [3–5], accumulating evidence suggests that ‘normal’ cells within the tumour stroma (including fibroblasts, endothelial and immune cells) play a major role in tumour development and progression [6]. Stromal features are prognostic in many tumour types [7–11], and expression of stromal genes has been shown to be associated with poor outcome in oesophageal cancer [12].

Fibroblasts are probably the most abundant stromal cells in most cancers, and are recognised to play a role

in the development and progression of a range of epithelial tumours [13]. Although fibroblasts within cancers comprise a phenotypically heterogeneous population, and the terminology is confusing [peritumour fibroblasts, cancer-associated fibroblasts (CAFs), 'activated' fibroblasts], 'activated' CAFs are commonly described as having a myofibroblastic phenotype; ie a secretory and contractile cell which expresses α -smooth muscle actin (α -SMA) [14,15]. These cells are responsible for the stromal desmoplasia observed in a number of solid cancers [16–18] and are associated with poor prognosis in several carcinoma types, including colorectal [10], breast [19], ovarian [20] and head and neck cancers [8]. CAFs regulate a number of tumour-promoting functions, including invasion [21] and angiogenesis [22], and may also affect tumour cell function by remodelling and generating tissue tension [23]. CAFs are predominantly derived from local fibroblasts, but it is clear that other cell types, including stellate cells, pericytes and circulating mesenchymal stem cells, can undergo myofibroblast transdifferentiation [24]. Irrespective of the progenitor cell, TGF β 1 signalling, in conjunction with increased mechanical resistance of the extracellular matrix (ECM), is central to the transdifferentiation process [25,26]. Notably, the stromal signature identified by Saadi and colleagues [12] in oesophageal cancer patients contained a predominance of inflammation and TGF β -related genes.

To date, little is known regarding the role of the tumour microenvironment, and in particular CAFs, in the development and progression of EAC [27,28]. In this study we investigated the prognostic and functional role of CAFs in EAC and provide new insights into the role of periostin in these processes.

Materials and methods

Tissue and cell collection, maintenance and RNAi

Tissue was collected and stored with ethical agreement and informed consent; 09/H0504/66. Fibroblasts were extracted from normal oesophagus and oesophageal adenocarcinoma and subcultured as previously described [29]. siRNA-mediated silencing of periostin was carried out using INTERFERin transfection reagent and two commercially available siRNA sequences (for full details, see supplementary material, Supplementary materials and methods).

Recombinant periostin

Periostin isoform 2 was subcloned and subsequently purified from Hek293F cells (for full details, see supplementary material, Supplementary materials and methods).

Immunohistochemistry

Optimisation and staining of cohorts on full-face sections, using mouse monoclonal α -SMA (M085129-2,

Dako, USA) and polyclonal rabbit anti-periostin (ab14041, Abcam, UK), was carried out on a Dako Link automated staining machine, according to the manufacturer's instructions. Sections were scored by a surgeon (TJU) and a pathologist (GT) blinded to patient outcome, using the following protocol: negative, no staining/<5%; moderate, patchy staining/5–50%; high, > 50%, as previously described [8].

Western blotting

Cells (FLO-1 or primary fibroblasts) were treated under different conditions including $\pm$ fibroblast conditioned medium, $\pm$ recombinant periostin, $\pm$ TGF β 1, $\pm$ TGF β R1 kinase inhibitor IV (Calbiochem), $\pm$ LY294002 (Sigma) and $\pm$ α v β 3 and α v β 5 integrin antibodies (R&D Systems). Cells were treated with either TGF β 1 or integrin receptor inhibitors for 1 h before treatment with recombinant proteins (TGF β 1 and periostin) or clarified conditioned medium (for full details of antibodies used, experimental conditions and western blotting, see supplementary material, Supplementary materials and methods).

Immunofluorescence

Immunofluorescence analyses were carried out as previously described [31]: primary antibodies, rabbit polyclonal anti-periostin (ab14041, Abcam) and mouse monoclonal anti- α -SMA (M085129-2, Dako); secondary antibodies, AlexaFluor 568 donkey anti-mouse IgG and AlexaFluor 488 goat anti-rabbit IgG (Molecular Probes).

Organotypic cultures

Organotypic cultures were carried out as previously described [29,32]. NOFs or CAFs were co-cultured with either OE33 or FLO-1 cells for 14 days. Fibroblasts were pretreated with POSTN siRNA sequence 1 (Ambion) before embedding in organotypic cultures, and matured for 10 days. Organotypics treated with 10 μ M LY294002 were matured for 14 days. Invasion was quantified and compared as previously described [33].

Transwell invasion

Transwell invasion assays were carried out as previously described [32]: 24 h-conditioned medium from NOFs or CAFs (plated in identical numbers) $\pm$ POSTN siRNA pre-treatment, $\pm$ TGF β 1 pre-treatment. Addition of 5 μ g/ml recombinant POSTN was used as the chemoattractant in the bottom chamber where indicated. Blocking antibodies for α v β 3 and α v β 5 integrins (10 μ g/ml; R&D Systems) and PI3K inhibitor LY294002 (10 μ M; Sigma) were added to the top chamber in combination with FLO-1 or OE33 cells for the duration of the experiment (72 h). All experiments were repeated three times, with four replicates/experiment. Normalisation was performed to the mean value of replicate 1 for all experimental conditions and data expressed as

percentage invasion compared to the appropriate control (ie negative control siRNA- or vehicle-treated cells).

Gel contraction

Gel contraction assays were carried out as previously described [8]: 0.5×10^6 normal or CAFs ($\pm$ POSTN siRNA knockdown) were seeded in collagen-1 gels.

Tumour xenografts

OE33 or OANC1 cells (5×10^6) $\pm$ NOFs or CAFs (1×10^6) were injected subcutaneously into the flanks of SCID mice (one injection/mouse) in a 1:1 mixture of PBS and Matrigel™ (BD Biosciences; for full details of this model, see supplementary material, Supplementary materials and methods).

Data acquisition and processing for network analysis

Weighted gene correlation network analysis (WGCNA) [34,35] was applied to microarray datasets generated on Affymetrix HG-U133A GeneChips from two independent studies (for full details of this analysis, see supplementary material, Supplementary materials and methods).

Statistical analysis

Statistical analysis was performed with SPSS® v 19 (SPSS, Chicago, IL, USA). Survival of patients was plotted using the Kaplan–Meier method and analysed using the log-rank test, with patients censored at last follow-up. Multivariate Cox logistic regression was used to assess the relationship between α -SMA and standard pathological variables after resection. Kruskal–Wallis and Mann–Whitney U- and *t*-tests were used to compare groups, as appropriate; $p < 0.05$ was considered statistically significant for all tests (* $p < 0.05$, ** $p < 0.01$).

Results

High α -SMA expression is common in EAC and correlates with poor overall survival following oesophageal resection

We used immunohistochemistry to examine the expression of α -SMA in the stroma of tumours from 183 patients following oesophageal resection (median follow-up = 4.5 years; 81 cancer-related deaths). Moderate/high expression of α -SMA (α -SMA-positive) was found in the majority of cases ($n = 171$). In 12 cases an α -SMA-negative stroma was observed, and this group of patients had a significant overall survival advantage [Figure 1A; mean survival α -SMA negative = 78.66 months (median not yet reached) versus α -SMA-positive = 48.14 months; $p = 0.016$ (median 39 months; 95% CI 29.2–48.8)]. The α -SMA-negative group was further analysed to exclude the possibility

that it was biased towards early-stage disease; this was not the case. The pathological stages according to the AJCC (7th edn) classification of EAC [36] for the patients in this group were: stage 0, one patient; stage IA, three patients; stage IIA, one patient; stage IIB, two patients; stage IIIA, two patients; stage IIIB, one patient; and stage IIIC, two patients. When α -SMA expression was compared against other commonly used indicators of prognosis following surgery (TNM stage [36,37] and resection clearance: R status) in a Cox regression model, α -SMA expression was the most predictive factor analysed: hazard ratio (HR) 7.1 (1.7–29.4); $p = 0.007$ (Table 1). Full details of the patient demographics are shown in Table S1 (see supplementary material).

Ex vivo analysis of primary oesophageal CAFs reveals a myofibroblast phenotype that can be induced by TGF β

CAFs were cultured directly from tumour tissue and NOFs from macroscopically and microscopically normal areas of mucosa at the proximal resection margin. NOFs and CAFs were characterised using cell-type specific markers, confirming a fibroblastic phenotype [vimentin-positive, cytokeratin-negative, CD31-negative (Figure 1B; see also supplementary material, Figure S1A) and desmin-negative (data not shown)]. CAFs expressed high levels of α -SMA, confirming a myofibroblast phenotype (Figure 1B). In an additional panel of primary fibroblasts, seven of eight CAFs expressed high levels of α -SMA compared with low or absent α -SMA levels in NOFs, in keeping with the immunohistochemical analysis of paraffin-embedded tissues (see supplementary material, Figure S1B). α -SMA stress fibre formation was observed in CAFs but not NOFs (Figure 1C). In gel contraction assays there was a significant reduction in gel size and weight in the presence of CAFs compared to NOFs (weight, $p < 0.01$), demonstrating the ability of CAFs to contract an *in vitro* ECM (Figure 1D).

Gene ontology analysis of the stromal signature in the progression of pre-invasive to invasive disease in EAC has previously identified TGF β signalling as a critical pathway in this transition [12]. Treatment of NOFs with TGF β 1 for 72 h resulted in high levels of α -SMA expression, stress fibre formation and increased gel contraction (gel weight NOFs 0.21 g versus NOFs + TGF β 1 0.15 g; $p < 0.01$), confirming myofibroblast transdifferentiation (Figure 1E). In addition, exposure of NOFs to conditioned medium from FLO-1 cells for 72 h resulted in a TGF β 1-dependent up-regulation of α -SMA (see supplementary material, Figure S1C).

CAFs promote EAC cell invasion *in vitro*

To determine whether CAFs secrete factors that promote EAC cell invasion, Transwell invasion assays were performed using EAC cell lines FLO-1 and OE33. Conditioned medium from NOFs or CAFs was used as a




Figure 1. CAFs in the microenvironment are important in EAC. (A) Kaplan–Meier curve of overall survival after resection in patients with α -SMA-positive versus α -SMA-negative tumours; representative IHC images of negative/low and positive/high are in the right-hand panel. (B) Western blot for pan-cytokeratin and vimentin in FLO-1, OE33 and primary oesophageal NOFs and CAFs. (C) Immunocytochemistry for α -SMA in primary oesophageal NOFs and CAFs. (D) Photograph of a representative gel contraction assay at 72 h and gel weight with the incorporation of CAFs compared to NOFs ($p < 0.01$; $n = 3$). (E) Western blot and immunocytochemistry for α -SMA in NOFs and NOFs + TGF β 1, and a representative gel contraction assay

chemoattractant in the lower chamber of the Transwell. CAFs-conditioned medium promoted a > two-fold increase in invasion of both EAC cell lines ($p < 0.05$; Figure 2A). The proliferation of FLO-1 cells exposed to either NOF- or CAF-conditioned medium was assessed by MTS assay, and no difference was observed (see supplementary material, Figure S2B). Using organotypic cultures as a more physiologically relevant model of tumour cell invasion [29], we further explored the role of EAC CAFs in this process. Invasion in these models was quantified and compared, taking into account the average depth of tumour invasion and the number and area of invading tumour islands [33]. Minimal invasion was seen in NOFs-containing gels, but in the presence

of CAFs, EAC cell invasion was significantly increased for both tumour cell lines [mean total area of invasion, arbitrary units ($n = 3$), FLO-1 + NOFs 2670.3 versus FLO-1 + CAFs 3862.3; $p < 0.001$; OE33 + NOFs 501 versus OE33 + CAFs 6238.3; $p < 0.001$; Figure 2B; see also supplementary material, Figure S2A].

CAF promote tumour growth *in vivo*

The ability of CAFs to support tumour growth *in vivo* was assessed using a xenograft model. The cell line FLO-1 was non-tumorigenic in this model and therefore experiments were performed using OE33 cells. Xenografts from OE33 cells injected subcutaneously, either alone ($n = 15$) or mixed with NOFs

Table 1. Cox regression analysis of α -SMA expression compared against other commonly used indicators of prognosis following oesophageal resection for EAC

Pathological variable	Hazard ratio	95% Confidence interval		Significance (p)
		Lower	Upper	
pT stage	1.49	1.14	1.95	0.003
pN stage	1.78	1.45	2.18	< 0.001
pM stage	1.57	0.62	3.96	0.343
Positive resection margin (R1)	1.31	0.81	2.11	0.271
α -SMA-positive stroma	7.07	1.70	29.39	0.007

($n=9$) or CAFs ($n=9$), did not grow uniformly and therefore the mice were culled when the tumour volume had reached 500 mm³, and groups were compared by Kaplan–Meier analysis. Mice receiving co-injections of OE33 cells and CAFs were culled significantly earlier (median survival OE33 + CAFs = 100 days versus OE33 + NOFs = 163.5 days; $p=0.04$; Figure 2C). Immunostaining for α -SMA confirmed the retained presence of CAFs in these tumours surrounding cytokeratin-positive tumour cells (Figure 2D).

Mice injected subcutaneously with an additional EAC cell line, OANC1 + CAFs ($n=4$), developed tumours that grew more rapidly than those injected with OANC1 + NOFs ($n=4$) (see supplementary material, Figure S2C).

Periostin is secreted by CAFs and promotes tumour cell invasion

Saadi and colleagues [12] recently described a stromal gene expression signature that is predictive of outcome in EAC. To complement this differential expression study, we applied WGCNA [38] to a publicly available EAC microarray dataset [39]. Seven modules of highly co-expressed genes were identified by unsupervised hierarchical clustering on the basis of topological overlap (TO) and labelled by colour (Table 2). The co-expression network was strongly preserved in an independent dataset [40].

ToppGene analysis indicated that the pink module was highly enriched for genes associated with fibroblasts (GSM777043; Bonferroni adjusted $p=3.1 \times 10^{-83}$). Concomitant with this finding, the top Gene Ontology (GO) category for the pink module was 'extracellular matrix organisation' (Table 2); among the enriched




Figure 2. CAFs promote EAC cell invasion *in vitro* and tumour growth *in vivo*. (A) Transwell invasion assays comparing the effect of NOFs and CAFs conditioned medium on invasion of the EAC cell lines FLO-1 and OE33. (B) Organotypic models of EAC comparing the effect of NOFs and CAFs to promote invasion of FLO-1 and OE33. (C) Kaplan–Meier curves of overall survival of mice injected with OE33 alone or in combination with NOFs or CAFs. Mice were culled when the tumour volume reached 500 mm³. (D) Immunohistochemistry for Pan-CK and α -SMA in tumour xenografts containing OE33 and CAFs

Table 2. Correlation matrix of seven modules (labelled by colour) of highly co-expressed genes that have been identified by unsupervised hierarchical clustering on the basis of topological overlap

Module colour	Number of genes	Module preservation (Zsummary)	Module Gene Ontology	Bonferroni (<i>p</i>)
Black	788	10	Intracellular transport	5.20E-11
Blue	1143	50	Skin development	1.10E-17
Brown	384	16	Cell cycle process	7.20E-06
Cyan	271	29	Nucleotide metabolic process	6.50E-06
Grey	745	13	DNA metabolic process	4.50E-15
Light green	467	39	Antigen processing and presentation	1.20E-06
Pink	202	23	Extracellular matrix organization	2.70E-34

The Zsummary is a composite statistic of density and connectivity preservation for the module: < 2, no preservation; 2–10, weak to moderate preservation; > 10, strong evidence of preservation.

genes were α -SMA, fibrillin 1 and periostin. Unsupervised hierarchical clustering of the ECM module genes differentiated between normal oesophageal epithelium and EAC (Figure 3A). These observations are consistent with the ECM module representing genes expressed by a CAFs-rich stroma.

The relative importance of each gene within its respective module can be estimated by a module membership measure (KME) [38]. Periostin had a high KME value (0.87), denoting centrality and importance within the ECM module; a full list of KME values is provided in Table S2 (see supplementary material). Of the top 86 nearest neighbours of periostin (TO threshold ≥ 0.15 ; Figure 3B), 52 of the genes were annotated for the GO categories ECM organization ($\text{adj}P = 4.1 \times 10^{-27}$), biological adhesion ($\text{adj}P = 7.0 \times 10^{-17}$) and locomotion ($\text{adj}P = 3.2 \times 10^{-8}$).

We therefore examined whether the tumour-promoting effects of CAFs are modulated through periostin. Conditioned medium from CAFs contained higher levels of periostin compared to NOFs by western blot and immunocytochemistry (Figure 3C). siRNA-silencing of POSTN in CAFs suppressed periostin expression and resulted in a >50% suppression of tumour cell invasion in Transwell assays ($p < 0.05$; Figure 3D). POSTN silencing in CAFs also resulted in complete loss of invasion by EAC cells in organotypic culture (mean total area of invasion, arbitrary units; $n = 3$; control siRNA 1187.7 versus POSTN siRNA 3581; $p < 0.001$; Figure 3E). To further confirm that the inhibition of tumour cell invasion was directly modulated through reduced periostin expression, we immunodepleted periostin from CAFs-conditioned medium and observed a similar reduction in invasion ($p < 0.05$). This was restored by addition of recombinant periostin (Figure 3F). Fibroblast proliferation after periostin silencing was not significantly different to control siRNA-treated cells (data not shown).

We had previously found that TGF β 1 treatment of NOFs generated a myofibroblastic phenotype (Figure 1D, E). TGF β 1-treated NOFs also up-regulated POSTN (Figure 3G) and promoted EAC invasion ($p < 0.01$). Periostin silencing did not affect the up-regulation of α -SMA in TGF β 1-treated NOFs (see supplementary material, Figure S3F). The increase in EAC invasion was again periostin-dependent and abrogated by POSTN down-regulation. Furthermore, the

addition of recombinant periostin to NOF-conditioned medium significantly increased EAC cell invasion in Transwell assays to levels comparable to CAF-conditioned medium (Figure 3H).

Periostin treatment of EAC cells results in integrin- and PI3K-dependent activation of Akt

We examined potential periostin-dependent downstream signalling pathways in EAC cells and found Akt to be consistently phosphorylated following periostin treatment. PI3K–Akt signalling has been reported to be a critical regulator of cell motility in several cancer types, including EAC, and we explored this response in more detail. Recombinant periostin was added to tumour cells and phosphorylation of Akt was observed at 30 min post-stimulation, which persisted for at least 120 min (Figure 4A). Periostin is a ligand for several integrins, including α v β 3 and α v β 5, and so we examined whether periostin-dependent Akt activation is modulated through integrin binding. After confirming the presence of α v β 3 and α v β 5 on the surface of EAC cells by western blot and flow cytometry (see supplementary material, Figure S3A, B), we found that phosphorylation of Akt in response to periostin was suppressed by blocking antibodies directed against α v β 3 or α v β 5 (Figure 4B). The suppression of Akt phosphorylation in periostin-treated cells, in the presence of the PI3K inhibitor LY294002 confirmed that Akt phosphorylation was PI3K-dependent (Figure 4C). Similar effects on Akt activation were observed in FLO-1 cells after 30 min treatment with CAFs-conditioned medium (see supplementary material, Figure S3E).

Periostin-dependent invasion is suppressed through inhibition of α v β 3, α v β 5 and PI3K

We repeated Transwell invasion assays to examine the effect of inhibiting α v β 3/ α v β 5–PI3K–Akt signalling in EAC cells. NOF-conditioned medium supplemented with recombinant POSTN or CAF-conditioned medium promoted EAC invasion (>3.5-fold; Figure 4D) and this was inhibited by the addition of α v β 3- or α v β 5-blocking antibodies, or a PI3K inhibitor, LY294002, to the tumour cells. Invasion of EAC cells in organotypic culture containing CAFs was significantly reduced in the presence of LY294002 (mean total area of invasion, arbitrary units ($n = 3$), FLO-1 + CAFs 11961




Figure 3. Periostin is secreted by CAFs and promotes EAC cell invasion. (A) Unsupervised hierarchical clustering of the ECM module genes differentiated between normal oesophageal epithelium and EAC. (B) Exported network weights in BioLayout Express^{3D}, graphically representing periostin as a central gene within the ECM module, with many connections to other ECM module genes and genes associated with the cell-cycle process. (C) Western blot of conditioned medium and immunocytochemistry, comparing the expression and secretion of periostin in NOFs and CAFs. (D) Transwell invasion assays, demonstrating the invasion of FLO-1 in response to CAF-conditioned medium $\pm$ periostin silencing, as indicated (* $p < 0.05$; ** $p < 0.001$), with western blot of conditioned medium normalized to cell number confirming periostin knockdown. (E) Organotypic cultures of FLO-1 and CAFs, with and without periostin silencing. (F) Transwell invasion assays of FLO-1 towards CAF-conditioned medium, with or without periostin immunodepletion and rescue with recombinant periostin, as indicated (* $p < 0.05$). (G) Transwell invasion assay of FLO-1 towards conditioned medium from NOFs or NOFs + TGF β 1, with and without periostin silencing, and western blot analysis of periostin expression under the same conditions (** $p < 0.001$). (H) Transwell invasion assay of FLO-1 towards conditioned medium from NOFs $\pm$ recombinant periostin or CAFs, as indicated (** $p < 0.001$)

versus FLO-1 + CAFs + LY294002 338.7; $p < 0.001$; Figure 4E). Proliferation of FLO-1 cells was not affected by treatment with LY294002 in organotypic assays, shown by Ki67 staining (Figure 4E), percentage of Ki67-positive cells in 10 high-power fields (vehicle = 87 ± 5 , LY294002 = 89 ± 3). This was confirmed by MTS assays across a range of concentrations (see supplementary material, Figure S3C). An increase in caspase-8 expression (not cleavage) was observed

(see supplementary material, Figure S3D). To confirm Akt activation in human EAC tumours, we performed immunohistochemistry (IHC) and observed pAkt in tumour cells, with the strongest staining adjacent to CAFs (Figure 4F). High stromal periostin expression was observed in the mouse xenograft model containing OE33 and CAFs, and activation of Akt was confirmed in this model by high pAkt staining in adjacent tumour cells (Figure 4G).




Figure 4. Periostin-dependent invasion of EAC cells is suppressed through inhibition of $\alpha v \beta 3$ and $\alpha v \beta 5$ integrins and PI3K. (A) Western blot for total and phospho-Akt in FLO-1 up to 120 min after stimulation with recombinant periostin. (B) Western blot for total and phospho-Akt in FLO-1, 30 min after periostin stimulation, in the presence or absence of blocking antibodies against integrins $\alpha v \beta 3$ or $\alpha v \beta 5$, as indicated. (C) Western blot for total and phospho-Akt in FLO-1, 30 min after periostin stimulation, in the presence or absence of the PI3K inhibitor LY294002. (D) Transwell invasion assays of FLO-1 towards NOFs or CAFs conditioned medium under varying conditions. Invasion towards NOF-conditioned medium is used as the internal control. Periostin was added to the NOF-conditioned medium and either LY294002 or blocking antibodies against integrins $\alpha v \beta 3$ or $\alpha v \beta 5$ were added to the FLO-1 cells, as indicated. (E) Organotypic models of FLO-1 + CAFs in the presence or absence of LY294002, including staining by H&E, pan-cytokeratin and Ki67. (F) Immunohistochemistry for p-Akt in representative human EAC tumours with strongest staining adjacent to CAFs. (G) Immunohistochemistry for periostin and p-Akt in tumour xenografts containing OE33 and CAFs

Periostin expression predicts survival after resection for EAC

Having established the importance of periostin to CAFs-induced EAC cell invasion *in vitro*, we examined our EAC patient cohort to confirm the presence of stromal periostin by IHC. Similar to α -SMA expression, moderate/high expression of periostin was observed in the majority of cases ($n = 166$; periostin-positive), with periostin localised to the cancer cell–stromal interface (Figure 5C, D), corresponding to areas of high α -SMA

expression (Figure 5D) in keeping with a myofibroblastic CAFs origin. Periostin expression was limited to blood vessel walls in normal oesophageal mucosa (Figure 5C).

In 17 cases there was no/minimal periostin staining (periostin-negative) and this group of patients had a significant overall survival advantage when compared with periostin-positive patients [Figure 5A; mean survival periostin-negative = 76.45 months (median not yet reached) versus periostin moderate/high = 46.80 months




Figure 5. Stromal periostin expression correlates with poor survival in EAC. (A) Kaplan–Meier curves of overall survival after resection in patients with periostin-positive versus periostin-negative tumours. (B) Kaplan–Meier curves of disease-free survival after resection in patients with periostin-positive versus periostin-negative tumours. (C) Immunohistochemistry for periostin expression in human normal oesophagus (limited to the walls of blood vessels) and EAC. (D) Immunohistochemistry to compare expression patterns of periostin and α -SMA in EAC

(median 39 months); $p = 0.009$]. We also examined the effect of periostin expression on disease-free survival (Figure 5B). Patients with no periostin staining in their resected tumours had a mean time to recurrence of 80.67 months (median not yet reached). Patients with high levels of periostin staining in the resected tumours experienced the shortest mean time to recurrence of 47.45 months (median 38 months; $p = 0.006$).

Discussion

The traditional model of EAC development describes progressive cellular dysplasia and accumulation of mutations in response to persistent acid reflux and inflammation [41]. Whole-genome and exome-sequencing studies are beginning to define the complexity of EAC, but suggest that the mutational burden may already be established in non-dysplastic BE

[42–44], meaning that the drivers for disease progression lie beyond gene mutations in the epithelial cells and that the stromal tissues play a critical role in disease development and progression.

However, very little is known about the role of the tumour microenvironment/stroma in oesophageal cancer [27,28]. CAFs are a heterogeneous cell type, and no single marker reliably identifies all CAFs. They are most commonly identified by α -SMA expression, indicative of an 'activated' myofibroblast-like phenotype. We found that the vast majority of patients with EAC have tumours with high or moderate levels of stromal α -SMA; this predicts poor survival and may account, in part, for the aggressive nature of the disease. Retrospective studies have intrinsic limitations and the uneven distribution of SMA expression in our cohort raises the possibility of a type 1 error; however, this may reflect the importance of the CAFs phenotype in EAC, which is clearly supported by the *in vitro* and *in vivo* data. EAC CAFs cultured from primary tumours

have an α -SMA-positive, contractile, myofibroblastic phenotype; they express a range of mesenchymal and fibroblast-specific markers, and promote EAC invasion *in vitro* and tumour growth *in vivo*. We provide evidence of a potential mechanism by showing that the invasion-promoting effect of CAFs is modulated, in part, through periostin, a secreted matricellular protein that plays an important role in tissue remodelling and collagen fibrillogenesis, interacting with ECM proteins such as fibronectin, tenascin C and collagen V, and with cell surface receptors, most notably integrins, including α v β 3, α v β 5 and α 6 β 4 [45–47]. We found that CAFs express high periostin levels *in vitro* and *in vivo*, and activate tumour cell PI3K–Akt signalling through integrin binding. Similar to α -SMA, periostin expression also predicts poor outcome in EAC patients.

A stromal gene-expression signature containing periostin has previously been shown to predict outcome in EAC [12]. However, most cancer studies have found periostin to be of tumour cell origin, with over-expression documented in a range of tumours, including lung, breast, ovary and pancreas [48]. Its functional role in cancer is not clear, although expression correlates with poor outcome in several cancers, suggesting a tumour-promoting effect, and, consistent with this, periostin has been reported to modulate a number of the hallmarks of malignancy [48]. Metastasising breast cancer cells induce periostin secretion in the cancer stem cell niche and require continued stromal periostin expression for cancer stem cell maintenance [49]. Importantly, disruption of the interaction between periostin and the integrin receptors α v β 3 and α v β 5 by periostin-binding DNA aptamers blocked signal transduction and reduced primary tumour growth and metastasis in an orthotopic breast cancer mouse model [50], suggesting that targeting periostin has therapeutic potential. Periostin is involved in remodelling of the ECM to support tumour development, invasion and metastasis [48]. Periostin has also been identified as a key component of an invasive signature in a three-dimensional (3D) organotypic model of oesophageal squamous cell carcinoma [51]. We have confirmed the importance of periostin in EAC biology. Applying WGCNA to publicly available EAC microarray datasets has identified periostin to have a 'nodal' position within ECM gene expression in EAC, with close associations with genes involved in cancer cell invasion, adhesion and locomotion.

Periostin contains a FAS1 domain that allows binding of α v-integrins and glycosaminoglycans *in vivo*. Interaction with these cellular receptors can lead to diverse downstream signalling effects in a context-dependent manner (NF- κ B, STAT3, PI3K–Akt and FAK), controlling the expression of many genes (including α -SMA, collagen and fibronectin) [52]. We found that periostin treatment of EAC cells results in integrin- and PI3K-dependent activation of Akt, and furthermore that periostin-dependent EAC cell invasion is suppressed through inhibition of α v β 3, α v β 5 and PI3K. These findings suggest not only that periostin is very likely to

be important for EAC cell invasion *in vivo*, but also that this is mediated by integrin–PI3K–Akt signalling. The PI3K signalling pathway integrates intra- and extracellular signals to modulate a multitude of downstream responses, effected by multiple substrates [53]. PI3K activation in response to integrin signalling is well documented in cancer, and there are some reports of Akt activation leading to tumour cell invasion in response to integrin-mediated periostin signalling in epithelial tumours, eg integrin α 5 β 1 in cholangiocarcinoma [47]. Canonical PI3K–Akt signalling is frequently dysregulated in cancer and can determine cell growth, proliferation, angiogenesis, migration and invasion [54]. The fact that periostin has been implicated in many of the same processes suggests that the PI3K–Akt pathway may act as a node for periostin signalling in cancer. Our findings suggest that in EAC it may be possible to target periostin–integrin–PI3K–Akt signalling at multiple levels with new and existing therapeutics. Further work is needed to confirm this hypothesis. For instance, it will be important to know whether periostin is prognostic in pretreatment biopsies from EAC, and whether or not the presence of periostin predicts response to neoadjuvant chemotherapy.

In conclusion, our study highlights the importance of the tumour stroma in EAC progression. The majority of EACs contain a prominent myofibroblastic (α -SMA-positive) CAFs-rich microenvironment, and stromal α -SMA expression is more significantly prognostic than conventional histopathological criteria. CAFs isolated from EAC have a functional myofibroblastic phenotype, and promote tumour cell invasion *in vitro* and growth *in vivo*, signalling to EAC cells via secretion of the ECM protein, periostin. Disruption of periostin signalling via integrin receptors and the PI3K–Akt pathway leads to abrogation of cancer cell invasion. This opens the possibility of targeting CAFs and their paracrine signals as treatment strategies in oesophageal cancer.

Acknowledgements

The work presented here is supported by a UK Medical Research Council Clinician Scientist award to TJU. The authors thank Dr Patrick Duriez (CRUK Protein Core Facility, University of Southampton) for the production of recombinant periostin; Mr Jamie Kelly, Mr James Byrne, Mr Ian Bailey, Sister Donna Sharland and Nina Hollings (Oesophagogastric Cancer Centre, University Hospital Southampton); the University of Southampton Experimental Cancer Medicine Centre Tumour Bank (ECMC), particularly Lisa Boulter and Kathy Potter; and the patients involved in this study.

Author contributions

TJU, AH, MD, EG, FN, MW, ST, CU, AM, MM, NC, JPB and GT were involved with study conception and

design, acquisition of data, analysis and interpretation of data and statistical analysis; ST carried out the microarray data analysis; TJU, JNP and GT obtained funding for the work and were responsible for administrative, technical and material support and study supervision; TJU, AH and GT drafted the manuscript; and all authors undertook critical revision of the manuscript for important intellectual content. TJU and GT take overall responsibility for the scientific content of the manuscript.

Abbreviations

AJCC, American Joint Committee on Cancer; BE, Barrett's oesophagus; CAF, cancer-associated fibroblast; EAC, oesophageal adenocarcinoma; ECM, extracellular matrix; IHC, immunohistochemistry; NOF, normal oesophageal fibroblast; POSTN, periostin; PI3K, phosphoinositide 3-kinase; α -SMA, smooth muscle actin; TGF, transforming growth factor; TNM, tumour node metastasis.

References

- Clinical Effectiveness Unit R, AUGIS, BSG, NCASP. National Oesophago-Gastric Cancer Audit. National Report. Report No. IC15100510. NHS Information Centre: Leeds, 2010.
- Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. *Lancet* 2013; **381**: 400–412.
- Wang DH, Souza RF. Biology of Barrett's esophagus and esophageal adenocarcinoma. *Gastrointest Endosc Clin N Am* 2011; **21**: 25–38.
- Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. *Gut* 2006; **55**: 1810–1820.
- Spechler SJ, Fitzgerald RC, Prasad GA, et al. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. *Gastroenterology* 2010; **138**: 854–869.
- Hu M, Polyak K. Microenvironmental regulation of cancer development. *Curr Opin Genet Dev* 2008; **18**: 27–34.
- De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. *J Exp Med* 2011; **208**: 469–478.
- Marsh D, Suchak K, Moutasim KA, et al. Stromal features are predictive of disease mortality in oral cancer patients. *J Pathol* 2011; **223**: 470–481.
- Surowiak P, Murawa D, Materna V, et al. Occurrence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. *Anticancer Res* 2007; **27**: 2917–2924.
- Tsujino T, Seshimo I, Yamamoto H, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. *Clin Cancer Res* 2007; **13**: 2082–2090.
- Wu Y, Grabsch H, Ivanova T, et al. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. *Gut* 2013; **62**: 1100–1111.
- Saadi A, Shannon NB, Lao-Sirieix P, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. *Proc Natl Acad Sci USA* 2010; **107**: 2177–2182.
- Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. *Semin Cell Dev Biol* 2010; **21**: 19–25.
- Massarelli G, Tanda F, Bosincu L, et al. Myofibroblasts in the epithelial-stromal junction of basal cell carcinoma. *Appl Pathol* 1983; **1**: 25–30.
- Ohtani H, Sasano N. Stromal cell changes in human colorectal adenomas and carcinomas. An ultrastructural study of fibroblasts, myofibroblasts, and smooth muscle cells. *Virchows Archiv A Pathol Anat Histopathol* 1983; **401**: 209–222.
- Kawashiri S, Tanaka A, Noguchi N, et al. Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. *Head Neck* 2009; **31**: 1346–1353.
- Merika EE, Syrigos KN, Saif MW. Desmoplasia in pancreatic cancer. Can we fight it? *Gastroenterol Res Pract* 2012; **2012**: 781765.
- Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. *Clin Cancer Res* 2008; **14**: 5995–6004.
- Yamashita M, Ogawa T, Zhang X, et al. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of α -smooth muscle actin correlates with worse clinical outcome. *Breast Cancer* 2012; **19**: 170–176.
- Lai D, Ma L, Wang F. Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. *Int J Oncol* 2012; **41**: 541–550.
- Lewis MP, Lygoe KA, Nystrom ML, et al. Tumour-derived TGF- β 1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. *Br J Cancer* 2004; **90**: 822–832.
- Vong S, Kalluri R. The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. *Genes Cancer* 2011; **2**: 1139–1145.
- Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. *Nat Cell Biol* 2007; **9**: 1392–1400.
- De Wever O, Demetter P, Mareel M, et al. Stromal myofibroblasts are drivers of invasive cancer growth. *Int J Cancer* 2008; **123**: 2229–2238.
- Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor- β 1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. *J Biol Chem* 2003; **278**: 12384–12389.
- Hinz B, Phan SH, Thannickal VJ, et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. *Am J Pathol* 2012; **180**: 1340–1355.
- Courrech Staal EF, Smit VT, van Velthuisen ML, et al. Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. *Eur J Cancer* 2011; **47**: 375–382.
- Schoppmann SF, Jesch B, Riegler MF, et al. Podooplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. *Clin Exp Metast* 2013; **30**: 441–446.
- Underwood TJ, Derouet M, White MJ, et al. A comparison of primary oesophageal squamous epithelial cells with HET-1A in organotypic culture. *Biol Cell* 2010; **102**: 635–644.
- Clemons NJ, Do H, Fennell C, et al. Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. *Dig Dis Sci* 2014; **59**: 78–88.
- Bergman LM, Birts CN, Darley M, et al. CtBPs promote cell survival through the maintenance of mitotic fidelity. *Mol Cell Biol* 2009; **29**: 4539–4551.
- Moutasim KA, Nystrom ML, Thomas GJ. Cell migration and invasion assays. *Methods Mol Biol* 2011; **731**: 333–343.
- Jenei V, Nystrom ML, Thomas GJ. Measuring invasion in an organotypic model. *Methods Mol Biol* 2011; **769**: 223–232.

34. Oldham MC, Konopka G, Iwamoto K, *et al.* Functional organization of the transcriptome in human brain. *Nat Neurosci* 2008; **11**: 1271–1282.
35. Chen Y, Zhu J, Lum PY, *et al.* Variations in DNA elucidate molecular networks that cause disease. *Nature* 2008; **452**: 429–435.
36. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual, esophagus and esophagogastric junction. *Ann Surg Oncol* 2010; **17**: 1721–1724.
37. UICC. *TNM Classification of Malignant Tumours*, 7th edn. Wiley-Blackwell: New York, 2009.
38. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinform* 2008; **9**: 559.
39. Kimchi ET, Posner MC, Park JO, *et al.* Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. *Cancer Res* 2005; **65**: 3146–3154.
40. Wang Q, Ma C, Kemmner W. Wdr66 is a novel marker for risk stratification and involved in epithelial–mesenchymal transition of esophageal squamous cell carcinoma. *BMC Cancer* 2013; **13**: 137.
41. Koppert LB, Wijnhoven BP, van Dekken H, *et al.* The molecular biology of esophageal adenocarcinoma. *J Surg Oncol* 2005; **92**: 169–190.
42. Weaver JM, Ross-Innes CS, Shannon N, *et al.* Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. *Nat Genet* 2014; **46**: 837–843.
43. Dulak AM, Stojanov P, Peng S, *et al.* Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. *Nat Genet* 2013; **45**: 478–486.
44. Agrawal N, Jiao Y, Bettegowda C, *et al.* Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. *Cancer Discov* 2012; **2**: 899–905.
45. Baril P, Gangeswaran R, Mahon PC, *et al.* Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the $\beta 4$ integrin and the PI3k pathway. *Oncogene* 2007; **26**: 2082–2094.
46. Li G, Jin R, Norris RA, *et al.* Periostin mediates vascular smooth muscle cell migration through the integrins $\alpha v \beta 3$ and $\alpha v \beta 5$ and focal adhesion kinase (FAK) pathway. *Atherosclerosis* 2010; **208**: 358–365.
47. Utispan K, Sonongbua J, Thuwajit P, *et al.* Periostin activates integrin $\alpha 5 \beta 1$ through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma. *Int J Oncol* 2012; **41**: 1110–1118.
48. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. *Cell Mol Life Sci* 2009; **66**: 2219–2230.
49. Malanchi I, Santamaria-Martinez A, Susanto E, *et al.* Interactions between cancer stem cells and their niche govern metastatic colonization. *Nature* 2012; **481**: 85–89.
50. Lee YJ, Kim IS, Park SA, *et al.* Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. *Mol Ther* 2013; **21**: 1004–1013.
51. Michaylira CZ, Wong GS, Miller CG, *et al.* Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. *Cancer Res* 2010; **70**: 5281–5292.
52. Conway SJ, Izuhara K, Kudo Y, *et al.* The role of periostin in tissue remodeling across health and disease. *Cell Mol Life Sci* 2014; **71**: 1279–1288.
53. Sheppard K, Kinross KM, Solomon B, *et al.* Targeting PI3 kinase/AKT/mTOR signaling in cancer. *Crit Rev Oncog* 2012; **17**: 69–95.
54. Bruhn MA, Pearson RB, Hannan RD, *et al.* AKT-independent PI3-K signaling in cancer – emerging role for SGK3. *Cancer Manag Res* 2013; **5**: 281–292.
55. Gautier L, Cope L, Bolstad BM, *et al.* affy – analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics* 2004; **20**: 307–315.
56. Oldham MC, Langfelder P, Horvath S. Network methods for describing sample relationships in genomic datasets: application to Huntington's disease. *BMC Syst Biol* 2012; **6**: 63.
57. Theodoridis A, van Dongen S, Enright AJ, *et al.* Network visualization and analysis of gene expression data using BioLayout Express (3D). *Nat Protoc* 2009; **4**: 1535–1550.

SUPPLEMENTARY MATERIAL ON THE INTERNET

The following supplementary material may be found in the online version of this article:

Supplementary materials and methods

Table S1. Clinicopathological characteristics of patient cohort for immunohistochemistry

Table S2. KME values for all of the proteins clustered in the ECM module

Figure S1. Further characterization of primary oesophageal fibroblasts

Figure S2. Additional organotypic and mouse xenograft model

Figure S3. Integrin $\alpha v \beta 3$ and $\alpha v \beta 5$ expressions were analysed in FLO-1 and OE33 cells using western blot, FACs and MTS proliferation assay